Advancing New Healthcare Solutions Through Collaboration
A preclinical study just published in Nature shows that the company's investigational vaccine has shown positive early data for eliciting an immune response against SARS-CoV-2, the virus that causes COVID-19.
Journalist Lisa Ling returns with top scientists, medical professionals and world leaders to answer your most pressing questions about COVID-19 including vaccine timing, your mental health, the economy and healthcare disparities in all new episodes. The groundbreaking series returns Tuesday, July 7 at 12pm ET. Watch as we broadcast LIVE from the 2020 International AIDS Conference.
This event will bring together entrepreneurs, start-ups, researchers, and scientists from across Europe and beyond. Hear from and interact with global and regional thought leaders, innovators and experts in immunology, and explore potential EMEA collaborations with Johnson & Johnson and other participants
Our COVID-19 Response
Johnson & Johnson Innovation is committed to helping patients, our partners and communities around the world manage the unprecedented impact of COVID-19.